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Gentamicin–Collagen Sponge for Infection
Prophylaxis in Colorectal Surgery
Elliott Bennett-Guerrero, M.D., Theodore N. Pappas, M.D.,
Walter A. Koltun, M.D., James W. Fleshman, M.D., Min Lin, Ph.D.,
Jyotsna Garg, M.S., Daniel B. Mark, M.D., M.P.H., Jorge E. Marcet, M.D.,
Feza H. Remzi, M.D., Virgilio V. George, M.D., Kerstin Newland, R.N.,
and G.R. Corey, M.D., for the SWIPE 2 Trial Group*

A BS T R AC T
BACKGROUND
From the Duke Clinical Research Institute
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This article (10.1056/NEJMoa1000837) was
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N Engl J Med 2010;363:1038-49.
Copyright © 2010 Massachusetts Medical Society.

Despite the routine use of prophylactic systemic antibiotics, surgical-site infection
continues to be associated with significant morbidity and cost after colorectal surgery. The gentamicin–collagen sponge, an implantable topical antibiotic agent, is
approved for surgical implantation in 54 countries. Since 1985, more than 1 million
patients have been treated with the sponges.
METHODS

In a phase 3 trial, we randomly assigned 602 patients undergoing open or laparoscopically assisted colorectal surgery at 39 U.S. sites to undergo either the insertion
of two gentamicin–collagen sponges above the fascia at the time of surgical closure
(the sponge group) or no intervention (the control group). All patients received
standard care, including prophylactic systemic antibiotics. The primary end point
was surgical-site infection occurring within 60 days after surgery, as adjudicated by
a clinical-events classification committee that was unaware of the study-group assignments.
RESULTS

The incidence of surgical-site infection was higher in the sponge group (90 of 300
patients [30.0%]) than in the control group (63 of 302 patients [20.9%], P = 0.01).
Superficial surgical-site infection occurred in 20.3% of patients in the sponge group
and 13.6% of patients in the control group (P = 0.03), and deep surgical-site infection in 8.3% and 6.0% (P = 0.26), respectively. Patients in the sponge group were
more likely to visit an emergency room or surgeon’s office owing to a wound-related
sign or symptom (19.7%, vs. 11.0% in the control group; P = 0.004) and to be rehospitalized for surgical-site infection (7.0% vs. 4.3%, P = 0.15). The frequency of
adverse events did not differ significantly between the two groups.
CONCLUSIONS

Our large, multicenter trial shows that the gentamicin–collagen sponge is not effective at preventing surgical-site infection in patients who undergo colorectal surgery; paradoxically, it appears to result in significantly more surgical-site infections.
(Funded by Innocoll Technologies; ClinicalTrials.gov number, NCT00600925.)
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P

ostoperative surgical-site infection
continues to be a significant problem after
general surgical procedures, especially co
lorectal surgery. Reported incidences of surgicalsite infection among patients who undergo co
lorectal surgery range from 8.2%1 to 26%,2 with
an incidence of approximately 18 to 20% in most
series.3-7 Postoperative surgical-site infection is
associated with a significant rate of complications and cost.8-10 Thus, prevention of these frequent infections has been the focus of numerous
strategies.2-7,11
The gentamicin–collagen sponge was developed to prevent and treat wound infections by
providing high gentamicin concentrations locally, avoiding the high systemic concentrations
associated with nephrotoxicity. The sponge’s collagen matrix biodegrades and disappears within
days to weeks. Pharmacokinetic data show that
implantation of one to five sponges (corresponding to a gentamicin dose of 130 to 650 mg) resulted in local-tissue gentamicin concentrations
of 170 to 9000 μg per milliliter. These concentrations exceed the minimum inhibitory concentrations for many microorganisms. Systemic concentrations of gentamicin, however, remained
below 2 μg per milliliter 24 hours after implantation.12
The sponge received marketing approval in
Germany in 1985 and is currently approved for
use in another 53 countries. Since 1985, more
than 2 million sponges manufactured by Innocoll
Technologies (Gallowston, Ireland) have been
used to treat more than 1 million patients across
a broad range of clinical indications. Several
studies suggest that the sponge may be effective
in the prevention and treatment of infections
after general surgery.6,13,14 In a single-center,
randomized trial, patients who underwent colo
rectal surgery and received a sponge had a 70%
decrease in surgical-site infection, as compared
with those who did not receive a sponge.6 The
current phase 3 trial was designed to confirm
these promising data and support regulatory approval in the United States.

Duke University coauthors wrote the study protocol, gathered and analyzed the data, vouch for the
accuracy and integrity of the data and analysis,
and wrote the manuscript. Institutional review
boards at participating institutions approved the
study protocol, and the study was performed in
accordance with it.
Patients

All patients provided written informed consent.
A complete list of inclusion and exclusion criteria, along with a detailed list of the surgical procedures, is provided in the Supplementary Appendix, available with the full text of this article
at NEJM.org. Inclusion criteria were an age of 18
years or older and having 1 of 13 types of colo
rectal surgery scheduled. Laparoscopically assisted procedures requiring an incision of at least
7 cm were allowed, a length that is consistent
with the use of a laparotomy “hand port” in many
so-called laparoscopic colorectal procedures. Exclusion criteria included the presence of a clinically significant concomitant surgical procedure,
use of a laparoscopic or other minimally invasive
surgical approach involving a laparotomy incision shorter than 7 cm, laparotomy within the
60-day period before the screening visit or a
planned second laparotomy within the 60-day
period after surgery, and a situation in which it
was technically impossible to insert two sponges
above the fascia.
Study Procedure

Study Treatment and Randomization

Each sponge (10 by 10 cm) contained 280 mg of
collagen and 130 mg of gentamicin. In patients
who were randomly assigned to receive a sponge,
two sponges were inserted anteriorly to the fascia, along the full length of the incision, immediately before closure of the surgical wound. To
facilitate placement in the wound, the sponges
could be cut into strips while dry. No sponges
were placed in control patients. Patients in the
sponge group in whom reexploration of the surgical site was necessary within 1 week after the
first surgery had two new sponges inserted at the
time of closure. All participating surgeons unMe thods
derwent a training and certification process that
study oversight
included the viewing of a video outlining proper
Patients were enrolled at 39 sites in the United use of the study sponge.
States. The study was coordinated by the Duke
Randomization occurred after the surgical
Clinical Research Institute (DCRI). The DCRI– incision had been made, with the use of a cenn engl j med 363;11
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tral randomization system. Control patients did
not receive a placebo sponge (a sponge containing collagen but not gentamicin), since bacteria
might have grown on a sponge that did not contain the antibiotic. Therefore, surgeons could
not be unaware of the study-group assignments,
but patients and members of the adjudication
committee did remain unaware.
Administration of Antibiotics and Bowel
Preparation

In accordance with published guidelines,15 the
protocol called for initiation of one of the following antibiotic regimens within 60 minutes before
incision: cefazolin plus metronidazole, cefoxitin,
or ciprofloxacin plus clindamycin or metronidazole. Dosing was based on body weight, and the
drugs were not to be continued for more than 24
hours after surgery. Preoperative oral antibiotics
were not required but could be added to the systemic antibiotic prophylaxis: oral neomycin plus
oral erythromycin or oral neomycin plus oral
metronidazole.15 The use of topical antibiotics,
other than the gentamicin in the sponge, was
prohibited in patients randomly assigned to receive the sponge. At least one of the following
bowel-preparation regimens was required: use of
a laxative (polyethylene glycol, sodium phosphate,
or a magnesium citrate–based regimen) or a highvolume enema.
Data Collection

Standard preoperative demographic and intraoperative characteristics were recorded, and we also
collected data on variables suspected to play a
role in surgical-site infection. The risk of infection was assessed with the use of the National
Nosocomial Infection Surveillance System.4,16
Primary and Secondary End Points

The primary study end point was surgical-site infection within the laparotomy wound during the
period from surgery through postoperative day 60.
Key secondary efficacy end points included the incidence of deep surgical-site infections, superficial
surgical-site infections, surgically treated surgicalsite infections (defined as infection treated with
any type of surgical intervention, including opening of the wound), postoperative hospital length
of stay, and ASEPSIS score through 60 days after
colorectal surgery.4,17,18 The validated ASEPSIS
score assigns points for nine variables related to
1040

n engl j med 363;11

of

m e dic i n e

infection, including use of antibiotics, drainage of
pus under local anesthesia, wound débridement
under general anesthesia, isolation of bacteria,
prolonged postoperative hospitalization, and findings on daily examination of the wound.4,17,18 The
minimum score is 0, and there is no theoretical
maximum score; higher scores indicate a worse
infection. We assessed the change in the serum
creatinine level from baseline, reporting the peak
level during the first 7-day postoperative period or
the period until hospital discharge if discharge
occurred before day 7. Patients assessed their pain
and wound healing according to a structured
questionnaire administered 30 and 60 days after
surgery. Data were recorded for death from any
cause at 60 days, visits to the emergency department or surgical office in association with woundrelated signs or symptoms, rehospitalization for
surgical-site infection, and serum gentamicin levels at several sites. Blood samples were obtained at
baseline (after incision) and then at 2±0.5, 6±0.5,
12±1, 24±2, and 48±2 hours after surgical-wound
closure for the determination of serum gentamicin levels.
Clinical Events Committee

The independent clinical events committee consisted of three independent infectious disease experts who were unaware of the study-group assignments. All suspected wound-infection events
were reviewed independently by two of the three
experts. Cases for which the two experts disagreed were reviewed by the third expert. Possible wound infections were identified by events
including signs of infection, administration of
postoperative antibiotics, rehospitalization, and
death. After review of blinded medical rec
ords,4,17,18 the committee ascertained the presence or absence, extent, and severity of all infections according to standardized criteria, including
those from the Centers for Disease Control and
Prevention4,16,17,19 and Itani and colleagues2: super
ficial infections that involved the skin and super
ficial fat but did not threaten the fascia, deep
infections involving deeper soft tissue of the incision and potentially threatening the fascia, and
organ-space infections below the fascia (which
are usually manifested as abscess). Data for infections not considered to be related to laparotomy
(e.g., perineal-incision infection, peristomal infection, infection at the intravenous catheter site,
or pneumonia) were not included in the analysis.
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674 Patients were enrolled

72 Were excluded
54 Had a planned change in surgery or no
longer met eligibility criteria
7 Withdrew consent
6 Were enrolled but not studied because
trial sample size was reached
4 Had an unknown reason
1 Was withdrawn by investigator

602 Underwent randomization

300 Were assigned to receive gentamicin–
collagen sponges
281 Received 2 sponges
15 Received only 1 sponge
4 Did not receive a sponge

302 Were assigned not to receive
sponges (control)
302 Received assigned intervention

5 Were lost to follow-up

3 Were lost to follow-up

300 Had data included in the intentionto-treat analysis
26 Were excluded from the perprotocol analysis
7 Did not meet eligibility criteria
15 Received only 1 sponge
4 Did not receive a sponge

302 Had data included in the intentionto-treat analysis
10 Were excluded from the perprotocol analysis because
eligibility criteria were not met

Figure 1. Enrollment, Randomization, and Follow-up of the Patients, According to Study Group.

Statistical Analysis

All analyses were performed by the statistical
team at the DCRI. Calculations during the planning phase indicated that enrollment of 592 patients (296 per study group) would be required to
detect a 50% relative reduction in the incidence
of surgical-site infection in the sponge group as
compared with the control group, with a power of
at least 85% and a two-sided type I error rate of
0.05. On the basis of previous trials, we assumed
a 16% incidence of surgical-site infection.
The primary analysis was based on intentionto-treat methods. We also performed a per-protocol analysis, as a prespecified secondary analysis, which included all patients who completed
the study and had no major deviations from the
prespecified protocol. We compared the primary
end point between the two study groups by means
of a two-sided chi-square test involving data
across all sites, after checking the treatment-byn engl j med 363;11

site interaction. In all secondary efficacy and sub
group analyses, a nominal two-sided P value of
less than 0.05 was considered to indicate statistical significance, and the results were considered to be descriptive.
Descriptive statistical comparisons between
the two study groups were performed with the
use of chi-square tests or Fisher’s exact test, as
appropriate, for categorical secondary efficacy
end points and with the use of analysis-of-variance techniques or Wilcoxon rank-sum tests, as
appropriate, for continuous secondary efficacy
end points. The log-rank tests were used to compare the time to first surgical-site infection between two study groups. Kaplan–Meier survival
estimates of the time to first surgical-site infection were also calculated.
No formal interim analysis was planned. An
independent data and safety monitoring committee monitored the trial on an ongoing basis.
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All statistical analyses were performed with the section primarily for colon or rectal carcinoma
use of SAS software (version 9.2).
(in 307 of 602 patients [51.0%]) or diverticulitis
or inflammatory bowel disease (217 of 602 patients [36.0%]). The study groups were balanced
R e sult s
with regard to baseline characteristics (Table 1)
Overall, 602 patients were enrolled at 39 U.S. as well as surgical preparation and intraoperasites between February 2008 and March 2009 tive characteristics (Table 2). Laparoscopically
(Fig. 1). Of the 300 patients randomly assigned to assisted surgery that was not converted to an
receive two sponges, 281 (93.7%), 15 (5.0%), and open procedure was performed in 51 of the 300
4 (1.3%) received two, one, and no sponges, re- patients (17.0%) in the sponge group and 58 of
spectively. A total of 8 of the 602 patients (1.3%; the 302 patients (19.2%) in the control group.
3 in the sponge group and 5 in the control group) Adjudicated surgical-site infection was more
were lost to follow-up at day 60.
likely to occur in association with open surgery
Patients in both groups underwent bowel re- (139 of 493 patients [28.2%]) than with laparoTable 1. Baseline Characteristics of the Patients, According to Study Group.*
Characteristic

Gentamicin–Collagen
Sponge (N = 300)

Control
(N = 302)

57.8

58.0

Age — yr
Median

45.5–67.7

47.4–67.0

White race — no. (%)†

IQR

272 (90.7)

273 (90.4)

American Society of Anesthesiologists score of 3 or 4 — no. (%)‡

132 (44.0)

126 (41.7)

Weight — kg
Median
IQR

79.5

80.0

67.9–93.0

69.4–93.2

26.8

27.2

23.8–30.8

24.0–30.8

96.0

96.5

Body-mass index§
Median
IQR
Waist circumference — cm
Median

86.0–106.7

86.4–106.7

Male sex — no. (%)

IQR

181 (60.3)

158 (52.3)

Hypertension — no. (%)

140 (46.7)

122 (40.4)

37 (12.3)

47 (15.6)

142 (47.3)

147 (48.7)

47 (15.7)

46 (15.2)

17 (5.7)

12 (4.0)

Diabetes — no. (%)
Smoking status — no. (%)
Current or previous
Current
Chronic obstructive pulmonary disease — no. (%)
Peripheral vascular disease — no. (%)

12 (4.0)

13 (4.3)

Previous laparotomy — no./total no. (%)

131/300 (43.7)

124/301 (41.2)

Previous radiation to abdomen — no. (%)

42 (14.0)

45 (14.9)

Chemotherapy within 6 wk before surgery — no. (%)

22 (7.3)

17 (5.6)

Corticosteroid use within 1 mo before surgery — no. (%)

25 (8.3)

17 (5.6)

History of abdominal fistula — no. (%)

10 (3.3)

10 (3.3)

5 (1.7)

5 (1.7)

Renal insufficiency — no. (%)¶
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Table 1. (Continued.)
Characteristic

Gentamicin–Collagen
Sponge (N=300)

Control
(N=302)

4.0

4.0

3.6–4.3

3.7–4.4

Preoperative laboratory values
Serum albumin — g/dl
Median
IQR
Serum glucose — mg/dl
Median
IQR

99

96

89–111

89–109

5.5

5.6

5.2–6.0

5.3–6.0

Serum glycated hemoglobin — %
Median
IQR
Hematocrit — %
Median
IQR

39.0

40.0

36.0–42.5

36.0–43.0

Serum creatinine — mg/dl
Median
IQR

0.9

0.9

0.8–1.1

0.8–1.0

97.7

97.7

97.0–98.2

97.0–98.2

Preoperative core temperature — °C
Median
IQR
Preoperative hospital stay — days
Median

0.0

0.0

0.0–0.0

0.0–0.0

0

32 (10.7)

38 (12.6)

1

166 (55.3)

159 (52.6)

2

102 (34.0)

105 (34.8)

3

0

0

IQR
NNISS score — no. (%)‖

* To convert the values for glucose to millimoles per liter, multiply by 0.05551. To convert the values for creatinine to
micromoles per liter, multiply by 88.4. IQR denotes interquartile range.
† Race was self-reported.
‡ The American Society of Anesthesiologists physical status classification score can range from 0 to 6, with higher scores
representing a worse condition. A score of 3 or 4 represents severe systemic disease.
§ The body-mass index is the weight in kilograms divided by the square of the height in meters.
¶ Renal insufficiency was defined as a preoperative serum creatinine level of 2.5 mg per deciliter (221 μmol per liter) or
more.
‖ The National Nosocomial Infection Surveillance System (NNISS) score can range from 0 to 3 points, with a higher
score representing a higher risk of infection. One point is awarded for an American Society of Anesthesiologists physical status classification score of 3 or more, one point is awarded for a contaminated or nonsterile operation, and one
point is awarded for a duration of surgery of more than 2 hours.

scopically assisted surgery (14 of 109 patients
[12.8%]).
In the primary analysis, surgical-site infections occurred more frequently in the sponge
group (90 of 300 patients [30.0%]) than in the
control group (63 of 302 [20.9%]) (P = 0.01) (Tan engl j med 363;11

ble 3). The incidence of superficial surgical-site
infection was 20.3% in the sponge group, versus
13.6% in the control group, and the incidence of
deep surgical-site infections was 8.3% versus
6.0%. Patients in the sponge group were more
likely than those in the control group to visit an
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Table 2. Characteristics of Surgical Preparation and Procedure, According to Study Group.*
Gentamicin–Collagen
Sponge (N = 300)

Control
(N = 302)

44 (14.7)

38 (12.6)

273 (91.0)

277 (91.7)

4 (1.3)

5 (1.7)

Other

9 (3.0)

12 (4.0)

None

17 (5.7)

16 (5.3)

Characteristic
Oral antibiotics administered preoperatively — no. (%)
Preoperative bowel preparation — no. (%)
Laxative use and complete bowel preparation
Enema

Preoperative shower with chlorhexidine soap — no. (%)

39 (13.0)

44 (14.6)

Hair at operative site not removed — no./total no. (%)

61/299 (20.4)

82/302 (27.2)

220 (73.3)

220 (72.8)

Preincision skin preparation — no. (%)
With povidone–iodine
With alcohol

42 (14.0)

42 (13.9)

With chlorhexidine-based agent

110 (36.7)

117 (38.7)

IV antibiotics administered within 60 min before incision

284 (94.7)

289 (95.7)

Antibiotic administered before incision — no. (%)
Aztreonam

0

1 (0.3)

Cefotetan

4 (1.3)

2 (0.7)

Cefazolin

89 (29.7)

92 (30.5)

Cefoxitin

111 (37.0)

105 (34.8)

6 (2.0)

6 (2.0)

Clindamycin
Ciprofloxacin
Metronidazole
Other

83 (27.7)

88 (29.1)

173 (57.7)

182 (60.3)

6 (2.0)

8 (2.6)

262/296 (88.5)

267/301 (88.7)

Left hemicolectomy

17 (5.7)

21 (7.0)

Transverse colectomy

12 (4.0)

11 (3.6)

Prophylactic IV antibiotics discontinued within 24 hr after incision —
no./total no. (%)
Surgical procedure performed — no. (%)

Segmental (sleeve) left colon resection

1 (0.3)

6 (2.0)

12 (4.0)

14 (4.6)

Total abdominal colectomy with ileostomy

18 (6.0)

15 (5.0)

Total abdominal proctocolectomy

23 (7.7)

15 (5.0)

Low anterior resection

77 (25.7)

105 (34.8)

Sigmoid resection

65 (21.7)

60 (19.9)

Nonemergency Hartman’s procedure

7 (2.3)

4 (1.3)

Colotomy with polypectomy distal to hepatic flexure

0

1 (0.3)

Total abdominal colectomy with ileorectal anastomosis

Colostomy takedown through laparotomy incision

21 (7.0)

15 (5.0)

Ileal pouch anal anastomosis with or without stoma

40 (13.3)

29 (9.6)

Abdominal–perineal resection of the rectum

22 (7.3)

16 (5.3)

Other
Laparoscopically assisted surgery†
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Table 2. (Continued.)
Gentamicin–Collagen
Sponge (N = 300)

Control
(N = 302)

16.0

14.0

9.3–23.0

9.0–20.0

Staples

239 (79.7)

219 (72.5)

Sutures

68 (22.7)

88 (29.1)

3 (1.0)

5 (1.7)

Characteristic
Laparotomy incision length — cm
Median
IQR
Method to close laparotomy incision — no. (%)

Glue
Duration of surgery — hr
Median
IQR
Abdominal surgical drain inserted — no. (%)

2.8

2.9

2.1–4.0

2.2–3.7

111 (37.0)

113 (37.4)

3.0

3.0

2.3–4.0

2.4–4.0

Crystalloid volume administered intraoperatively — liters
Median
IQR
Colloid volume administered intraoperatively — liters
Median
IQR
Nitrous oxide used — no. (%)

0.0

0.0

0.0–0.5

0.0–0.5

33 (11.0)

18 (6.0)

53

52

46–70

47–65

FiO2 during surgery — %
Lowest value
Median
IQR
Estimated average value
Median
IQR
Administered any dexamethasone in perioperative period — no. (%)

60

60

54–87

52–77

31 (10.3)

41 (13.6)

140

142

Peak serum glucose in first 24 hr after surgery — mg/dl
Median
IQR
Perioperative allogeneic red-cell transfusion — no. (%)

119–167

116–173

48 (16.0)

56 (18.5)

36.5

36.4

Core temperature at end of surgery — °C
Median
IQR
Core temperature at end of surgery ≥36°C — no./total no. (%)

36.2–36.8

36.2–36.8

264/297 (88.9)

250/297 (84.2)

* To convert the values for glucose to millimoles per liter, multiply by 0.05551. FiO2 denotes fraction of inspired oxygen,
IQR interquartile range, and IV intravenous.
† Laparoscopically assisted surgery did not include procedures in which the laparoscopic approach was abandoned
(i.e., conversion to open laparotomy).
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emergency department or surgical office with a
wound-related sign or symptom (19.7 vs. 11.0%,
P = 0.004); rehospitalization for surgical-site infection occurred in 7.0% of patients in the sponge
group and 4.3% of patients in the control group
(P = 0.15). Times to surgical-site infection are
shown in Figure 2.
The frequency of adjudicated surgical-site infection was 44.7% (134 of 300 patients) in the
sponge group, versus 34.4% (104 of 302 patients)
in the control group, as assessed by the site investigators (which is similar to results on the basis
of assessment by the clinical events committee).
Analyses performed in the per-protocol population
of 566 patients yielded results similar to those
for the intention-to-treat population (Table 3).
Among patients in the per-protocol population with adjudicated surgical-site infection, potential pathogens were isolated in samples from
44 patients in the sponge group and 28 patients
in the control group (Table 1 in the Supplementary Appendix). The organisms found to be most
frequently resistant to gentamicin include Enterococcus faecalis (in 3 of 9 isolates), Enterococcus faecium
(1 of 3 isolates), Escherichia coli (1 of 9 isolates),
Proteus mirabilis (1 of 5 isolates), and Staphylococcus
epidermidis (9 of 12 isolates) (Table 2 in the Supplementary Appendix). All but 2 of the 15 resistant isolates were cultured from patients in the
sponge group.
Peak serum gentamicin levels ranged from
0.9 to 4.7 μg per milliliter (mean, 2.4) and decreased to a mean (±SD) of 0.4±0.4 μg per milliliter by 48 hours after sponge insertion (Fig. 1
in the Supplementary Appendix). The mean percent increase from baseline in the peak serum
creatinine level was similar in the two groups
(14.8±42.6% in the sponge group and 15.4±45.1%
in the control group).
Eighteen patients required reexploration of
the surgical wound: 11 patients in the sponge
group and 7 patients in the control group. Exclusion of data from these patients from the primary
analysis did not change the overall results (with
a rate of adjudicated surgical-site infection of
29.4% in the sponge group vs. 21.4% in the control group, P = 0.03). Six patients had died by day
60 (1 patient in the sponge group and 5 patients
in the control group). No significant differences
were found between the two groups regarding
serious adverse events (Table 3 in the Supplementary Appendix).
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Given the increase in surgical-site infection
observed with the gentamicin–collagen sponge,
a post hoc analysis was performed to investigate
a possible mechanism for this effect. We speculated that the presence of sponge mass (assuming two sponges were placed) may have been a
mechanical barrier to early wound healing that
promoted infection. However, no clear association was seen between surgical-site infection and
incision length, waist circumference, or bodymass index according to study group (results not
shown). In addition, there was no overt difference in the degree of wound healing between
the two groups at 30 or 60 days, on the basis
of data from a structured patient questionnaire
(Table 4 in the Supplementary Appendix).

Discussion
The gentamicin–collagen sponge, developed to
deliver a high local and wound concentration of
gentamicin, has undergone testing throughout
northern Europe. For example, a single-center,
nonblinded study involving 221 patients undergoing colorectal surgery showed a 70% relative
reduction of the incidence of surgical-site infection with the use of the sponge (18.4%, vs. 5.6%
with no sponge; P<0.01).6 These results served as
strong preliminary data for our trial. However,
the results of our large, randomized clinical trial
showed that use of the sponge, as compared with
no sponge, did not reduce the incidence of surgical-site infection in patients undergoing colo
rectal surgery. Contrary to initial expectations,
patients randomly assigned to undergo sponge
placement, as compared with those who did not
undergo sponge placement, had a higher incidence of surgical-site infection, were more likely
to visit an emergency room or surgical office for
a wound-related sign or symptom, and more frequently underwent rehospitalization for surgicalsite infection. These results raise important new
questions about the best method for reducing the
risk of this important complication, which still
affects about one in five patients undergoing colo
rectal surgery, despite skin decontamination
and administration of systemic antibiotics.3-7
Our data do not allow us to identify with
certainty the cause of the lack of efficacy we
observed. However, we can speculate that several factors may have been operational. First,
though the microorganisms cultured from in-
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Table 3. Surgical-Site Infection (SSI) and Other Postoperative End Points through Postoperative Day 60, According to
Study Group.*
Gentamicin–Collagen
Sponge (N = 300)

Characteristic

Control
(N = 302)

P Value

Intention-to-treat analysis
SSI — no. of patients (%)
Any (primary end point)

90 (30.0)

63 (20.9)

0.01

Surgically treated

71 (23.7)

49 (16.2)

0.02

Superficial

61 (20.3)

41 (13.6)

0.03

Deep

25 (8.3)

18 (6.0)

0.26

4 (1.3)

4 (1.3)

Organ space
ASEPSIS score†

1.00
0.17

Median
IQR

0.0

0.0

0.0–10.0

0.0–4.0

Rehospitalization for SSI — no. of patients (%)

21 (7.0)

13 (4.3)

0.15

Visit to ER or physician for wound-related sign or symptom
— no. of patients/total no. (%)

57 (19.7)

31 (11.0)

0.004

Postoperative hospital length of stay — days

6.0 (5.0–8.0)

6.0 (4.0–8.0)

0.44

Gentamicin–Collagen
Sponge (N = 274)

Control
(N = 292)

Median
IQR

Per-protocol analysis
SSI — no. of patients (%)
Any (primary end point)

83 (30.3)

62 (21.2)

0.01

Surgically treated

68 (24.8)

48 (16.4)

0.01

Superficial

56 (20.4)

41 (14.0)

0.04

Deep

23 (8.4)

18 (6.2)

0.31

4 (1.5)

3 (1.0)

0.72

Organ space
ASEPSIS score†

0.19

Median
IQR
Rehospitalization for SSI — no. of patients (%)

0.0

0.0

0.0–10.0

0.0–5.0

20 (7.3)

Visit to ER or physician for wound-related sign or symptom
— no. of patients/total no. (%)

12 (4.1)

53/265 (20.0)

30/272 (11.0)

6.0

6.0

5.0–8.0

4.0–8.0

Postoperative hospital length of stay — days

0.10
0.004
0.48

Median
IQR

* ER denotes emergency room, and IQR interquartile range.
† The ASEPSIS score reflects nine variables related to the infection, including use of antibiotics, drainage of pus under local anesthesia, wound débridement under general anesthesia, isolation of bacteria, prolonged postoperative hospitalization, and findings on daily examination of the wound. The minimum score is 0, and there is no theoretical maximum
score; higher scores indicate a worse infection. The mean (±SD) score was 6.1±10.4 in the sponge group and 5.2±11.0
in the control group in the intention-to-treat population and 6.0±10.2 and 5.3±11.1, respectively, in the per-protocol
population.
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Figure 2. Kaplan–Meier Estimates of the Number of Days from Surgery
to Surgical-Site Infection (SSI) within the 60-Day Postoperative Period,
According to Study Group.

fected surgical wounds were similar in distribution between the two study groups (Table 1 in
the Supplementary Appendix), cultures from the
sponge group contained significantly more resistant bacteria than cultures from the control
group. These findings may be partly explained
by the results of the time-kill testing (which
measures the antimicrobial activity of a drug)
independently performed by the sponsor with
doses of 100 μg and 300 μg of gentamicin sulfate per milliliter (Prior D: personal communication). Regrowth of S. aureus, coagulase-negative
staphylococci, and enterococcus was found at 24
hours. These results are consistent with the conclusion by Tam and colleagues20 that gentamicin
should be administered every 8 hours to eliminate staphylococci and enterococci, in contrast to
administration every 24 hours, which is effective
against gram-negative bacilli. Second, gentamicin may elute too rapidly to increase the efficacy
of systemic preoperative antibiotics. In support
of this hypothesis are data showing low wound
and local levels of gentamicin 12 hours after
sponge insertion.21 We found what appeared to
be a transient early benefit of the sponge (Fig. 2),
with a subsequent reversal in that effect, which
may be consistent with the failure of the sponge
to provide a sustained local level of gentamicin.
A sponge with depleted antibiotic levels could
harbor bacteria and thereby increase the risk of
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infection. Third, the collagen used to construct
the sponges we used could have stimulated a
deleterious local effect. An additional possibility
is that the collagen may have been a mechanical
barrier to rapid and effective closure of the
wound, thus providing additional time for bacterial penetration to occur. Arguing against this
hypothesis is the fact that our post hoc analyses
showed no clear association between treatment
effect and wound length or surrogates for wound
depth (waist circumference and body-mass index).
If the sponge is not effective, why did results
of an earlier study by Rutten and Nijhuis6 suggest such a strong treatment benefit? In the
previous study, the duration of follow-up was not
reported; duration could be a factor, since evidence of harm became apparent in our study
only 3 weeks after surgery. In addition, the previous study used a lower dose of gentamicin (one
sponge containing 130 mg of gentamicin) than
was used in our study (two sponges, each containing 130 mg of gentamicin). However, it is
unclear why our use of a higher dose of gentamicin would yield such different results, unless harm was mediated by a mechanical effect
of the sponge. An important difference between
the study by Rutten and Nijhuis and ours is that
they did not use several quality-control measures
(e.g., verification of data from on-site monitoring and source documents, central adjudication
of end points by an independent committee that
was unaware of the group assignments, and the
inclusion of a large number of surgical sites [1, vs.
39 in our study] and patients). The discrepancy
in results may be related to the fact that findings
from positive single-center trials are often not
confirmed in larger multicenter trials.22 Furthermore, differences among races and ethnic groups
and among regions may have resulted in the different results between our U.S.-based trial and
previous studies.23
A limitation of our trial is that it was designed to study the prevention of infection, so its
results cannot be used to address whether the
sponge is effective for the treatment of infection.13 Another limitation of our trial is that it
did not address the efficacy of sponge placement
below the fascia.
In conclusion, our large, multicenter trial
shows that the gentamicin–collagen sponge is
not effective at preventing surgical-site infection
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in patients undergoing colorectal surgery and,
as compared with the placement of no sponges,
appears to result in significantly more surgicalsite infections.
Supported by Innocoll Technologies.
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